Axsome Therapeutics has hit a costly snag in its mission to bring esreboxetine to market for fibromyalgia. | Axsome ...

The FDA rejected Axsome's AXS-14 fibromyalgia, prompting a new trial and pushing the expected drug launch to 2028.

Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous ...

FDA concluded that AXS-14’s New Drug Application was not sufficiently complete for substantive review, citing concerns with ...

Investing.com -- Shares of Axsome Therapeutics Inc (NASDAQ: AXSM) fell 1.2% following the U.S. Food and Drug Administration’s (FDA) Refusal to File (RTF) letter regarding the company’s New Drug ...

T'puram: The new Coast Guard jetty at Vizhinjam was inaugurated by director general S Paramesh in the presence of inspector ...

Movember ? the world's leading men's health charity ? has released the Real Face of Men's Health Report (the report) detailing new findings on the state of men's health in Canada. The report reveals ...

Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced ...

Shares of Axsome Therapeutics, Inc. (AXSM) slumped 3% in the pre-market session on Monday after the company said that it has ...

Village Farms International, Inc. ("Village Farms" or the "Company") today announced that it received formal notice from The Nasdaq Stock Market LLC ("Nasdaq") informing the Company that it has ...

In response to the FDA's feedback, Axsome plans to conduct an additional controlled trial that will use a fixed-dose paradigm ...

A revolutionary STI test developed by UK-based Linear Diagnostics is on track to dramatically reduce the time it takes to ...